for Broad-Spectrum “Universal” Influenza Vaccine in Japan.
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine candidates in Japan.
Osivax is to receive upfront payment for execution of the license option agreement, and is eligible for an additional upfront payment, development and regulatory milestone payments, as well as tiered royalties upon execution of the license agreement.